Alzamend Neuro Statistics
Alzamend Neuro (9ZT) Stock Statistics & Valuation Metrics
Total Valuation
Alzamend Neuro has a market cap or net worth of EUR 5.43M. The enterprise value is EUR 1.21T.
- Market Cap
- EUR 5.43M
- Enterprise Value
- EUR 1.21T
Share Statistics
Alzamend Neuro has 4,825,723 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,825,723
- Owned by Insiders
- 2.65%
- Owned by Institutions
- 24.74%
Financial Efficiency
Alzamend Neuro’s return on equity (ROE) is -11.96 and return on invested capital (ROIC) is -1195.68%.
- Return on Equity (ROE)
- -11.96
- Return on Assets (ROA)
- -4.22
- Return on Invested Capital (ROIC)
- -1195.68%
- Return on Capital Employed (ROCE)
- -11.96
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.46M
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Alzamend Neuro is -0.50. Alzamend Neuro’s PEG ratio is -0.00.
- PE Ratio
- -0.50
- PS Ratio
- 0.00
- PB Ratio
- 0.88
- Price to FCF
- -0.80
- Price to Operating Cash Flow
- -0.75
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Alzamend Neuro had revenue of 0 and earned -8.77M in profits. Earnings per share was -2.63.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -8.77M
- Pretax Income
- -8.77M
- Net Income
- -8.77M
- EBITDA
- -8.66M
- Earnings Per Share (EPS)
- -2.63
Cash Flow
In the last 12 months, operating cash flow was -6.84M and capital expenditures 0, giving a free cash flow of -6.84M billion.
- Operating Cash Flow
- -6.84M
- Free Cash Flow
- -6.84M
- Free Cash Flow per Share
- -1.53
Dividends & Yields
Alzamend Neuro pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -120.18%
- Earnings Yield
- -172.13%
Stock Price Statistics
- Beta
- 0.00
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 194.40
- 200-Day Moving Average
- 194.40
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Alzamend Neuro upcoming earnings date is ―, Before Open (Confirmed).
- Last Earnings Date
- Mar 16, 2023
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Alzamend Neuro as a current ratio of 1.31, with Debt / Equity ratio of 0.00%
- Current Ratio
- 1.31
- Quick Ratio
- 1.31
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.08
- Interest Coverage Ratio
- 1324.50
Taxes
In the past 12 months, Alzamend Neuro has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Alzamend Neuro EV to EBITDA ratio is 0.21, with an EV/FCF ratio of 0.28.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.21
- EV to Free Cash Flow
- 0.28
- EV to Operating Cash Flow
- 0.28
Balance Sheet
Alzamend Neuro has EUR 7.59M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 7.59M billion.
- Cash & Marketable Securities
- EUR 7.59M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 7.59M
- Net Cash Per Share
- EUR 1.57
- Tangible Book Value Per Share
- EUR 1.30
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Alzamend Neuro is EUR 23.32, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 23.32
- Price Target Upside
- 88.01% Downside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―

